Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

Pablo Tebas, William G. Powderly, Sherry Claxton, Donna Marin, Woraphot Tantisiriwat, Steven L. Teitelbaum, Kevin E. Yarasheski

Research output: Contribution to journalArticle

449 Scopus citations

Abstract

Background: The use of highly active antiretroviral therapy (HAART) has been associated with multiple metabolic complications whose pathogenesis is poorly understood at the present time. Methods: We performed a cross-sectional analysis of whole-body, lumbar spine (L1-L4) and proximal femur bone mineral density in 112 male subjects (HIV-infected patients on HAART that included a protease inhibitor, HIV-infected patients not receiving a protease inhibitor and healthy seronegative adults) using dual energy x-ray absorptiometry. Results: Men receiving protease inhibitors had a higher incidence of osteopenia and osteoporosis according to World Health Organization definitions: relative risk = 2.19 (95% confidence interval 1.13-4.23) (P = 0.02). Subjects receiving protease inhibitors had greater central:appendicular adipose tissue ratios than the other two groups (P < 0.0001). There was no relationship between the central:appendicular fat ratio and the lumbar spine or proximal femur bone mineral density t- or z- scores, suggesting that osteoporosis and body fat redistribution are independent side effects of HAART. Conclusions: Osteopenia and osteoporosis are unique metabolic complications associated with protease inhibitor-containing potent antiretroviral regimens, that appear to be independent of adipose tissue maldistribution. (C) 2000 LippincottWilliams and Wilkins.

Original languageEnglish
Pages (from-to)F63-F67
JournalAIDS
Volume14
Issue number4
DOIs
StatePublished - Apr 13 2000

Keywords

  • Adiposity
  • Aspartyl protease inhibitors
  • Bone densitometry
  • Bone mineral metabolism
  • HIV infection
  • Osteoporosis

Fingerprint Dive into the research topics of 'Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy'. Together they form a unique fingerprint.

  • Cite this